Is There any Alternative Receptor for SARS-CoV-2?

(Pages: 247-250)
Mahtab Shahriari Felordi, M.Sc, 1Arash Memarnejadian, Ph.D, 2Mustapha Najimi, Ph.D, 3,*Massoud Vosough, M.D., Ph.D., 1,*
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Sernova Corp., London, Ontario, Canada
Laboratory of Pediatric Hepatology and Cell Therapy, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Brussels, Belgium
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
Sernova Corp., London, Ontario, Canada
Laboratory of Pediatric Hepatology and Cell Therapy, Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain, Brussels, Belgium
*Corresponding Addresses: Laboratory of Pediatric Hepatology and Cell Therapy Institute of Experimental and Clinical Research Université Catholique de Louvain B-1200 Brussels Belgium Department of Regenerative Medicine Cell Science Research Center Royan Institute for Stem Cell Biology and Technology ACECR Tehran Iran Emails:mustapha.najimi@uclouvain.be,masvos@royaninstitute.org
The Cell Journal (Yakhteh) is an open access journal which means the articles are freely available online for any individual author to download and use the providing address. The journal is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported License which allows the author(s) to hold the copyright without restrictions that is permitting unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Shahriari Felordi Mahtab, Memarnejadian Arash, Najimi Mustapha, Vosough Massoud. Is There any Alternative Receptor for SARS-CoV-2?. Cell J. 2021; 23(2): 247-250.

Abstract

Angiotensin-converting enzyme II (ACE2) in association with type II transmembrane serine protease (TMPRSS2) is considered the main receptor of SARS-CoV-2. However, considering the clinical complications of COVID-19 in different organs, there is no strong association between the abundance of ACE2/TMPRSS2 co-expression and clinical features of the disease and the severity of complications. Since SARS-CoV-2 affects certain organs that lack or have low expression of ACE2/TMPRSS2, it may be possible that the virus employs other receptors for colonization and entry. Based on recent studies, glucose-regulated protein 78 (GRP78) can be a potential alternative receptor for SARS-CoV-2 entry. In this letter, supporting evidence proposed GRP78 as an alternative receptor in SARS-CoV-2 infection.